Whole Exome (WE) sequencing data files for H_NO-JB001

Data Access Requirements for: Therapeutic Resistance to PI3K-alpha Inhibitors

February 2, 2015EGA (European Genome-phenome Archive) Project Name: Convergent loss of PTEN leads to clinical resistance to a PI(3)-alpha inhibitorPI Name: Maurizio ScaltritiProtocol#: 06-107 and 00-032The Memorial Sloan Kettering Cancer Center IRB hereby assures that the submission of the data from the study entitled " Convergent loss of PTEN leads to clinical resistance to a PI(3)-alpha inhibitor" from cases consented to either 06-107 or 00-032 meets the following expectations, as defined in the Policy (or Sharing Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS): •The data submission is consistent with all applicable laws and regulations, as well as institutional policies.•The appropriate research uses of the data and the uses that are specifically excluded by the informed consent documents are delineated below:Data Use Limitation(s): General Research Use •The identities of research participants will not be disclosed to the EGA data repository.•An Institutional Review Board and/or Privacy Board, as applicable, reviewed the investigator's proposal for data submission and assures that:o The protocol for the collection of genotype and phenotype data to be submitted to EGA was consistent with 45 CFR Part 46.o Submission of the data to EGA and subsequent sharing for research purposes are consistent with the informed consent of the study participants from whom the data were obtained.o The risks to individuals, their families, and groups or populations associated with the data submitted to EGA have been considered.o The investigator's plan for de-identifying datasets is consistent with the standards outlined in the NIH Policy.The genotype and phenotype data proposed to be submitted may be used under the following:Unrestricted use